Despite several in vitro studies showing that VEGF-induced angiogenetic processes increase plaque instability, the administration of anti-angiogenic drugs (mainly anti-VEGF) for cancer therapy causes adverse cardiovascular effects in human studies. The gene discussed is VEGFA; the disease is cancer.